Kidney Neoplasms Clinical Trial
Official title:
Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy
Partial nephrectomy is considered the standard treatment for renal tumors smaller than 7 cm. With the evolution of image diagnostic tools and dissemination of its use, smaller tumors are being commonly diagnosed and treated. The partial open nephrectomy is still considered the gold standard technique for nephron sparing surgery, especially when the surgeon is not experienced with the minimally invasive surgery. In the last 15 years, uncountable minimally invasive techniques were developed, including the laparoscopic partial nephrectomy. The objective of this study is compare the partial laparoscopic nephrectomy to open partial nephrectomy in terms of perioperative, oncologic and functional outcomes. A balanced randomized prospective trial will be conducted. One group of patients will be submitted to to open partial nephrectomy while the other group of patients will be submitted to laparoscopic partial nephrectomy. A randomized prospective trial comparing the two techniques is necessary to determine the differences in outcomes between them and if the laparoscopic partial nephrectomy can be performed without harms to the patients.
Status | Recruiting |
Enrollment | 242 |
Est. completion date | January 2020 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with renal tumor cT1N0M0; (<7 cm) - Normal renal function (serum creatinine <1.2 and glomerular filtration rate> 60mL/min/1.73m2) - Tumor only Exclusion Criteria: - Functional or anatomical solitary kidney - Horseshoe kidney, ectopic or malformed - Clinical contraindication to surgery - Contraindication to laparoscopic surgery - Association with other renal pathologies - Evidence of lymph node or systemic disease in preoperative staging |
Country | Name | City | State |
---|---|---|---|
Brazil | Cancer Institute of the State of São Paulo | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Surgical Complications | 6 months | ||
Secondary | Renal Function | 2 years | ||
Secondary | Oncological outcomes | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
Terminated |
NCT01413607 -
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
|
Phase 4 | |
Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00226980 -
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A |